The 2022 Tandem Meetings | Prognostic value of early bone marrow MRD status in CAR-T therapy for multiple myeloma
Radhika Bansal
• 11 Apr 2022
Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, gives a summary of the results of a study evaluating the prognostic value of early bone marrow (BM) measurable residual disease (MRD) status in patients with multiple myeloma treated with CAR-T therapy. The study found that early BM MRD negativity was a prognostic factor for survival and response regardless of cellularity and free light chain normalization at month one. In addition, patients who are MRD-positive at month one were found to have a low likelihood of achieving MRD negativity. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
